CNS Drugs

, Volume 17, Issue 15, pp 1081–1091

Clinical Potential of Omega-3 Fatty Acids in the Treatment of Schizophrenia

  • Robin Emsley
  • Piet Oosthuizen
  • Susan J. van Rensburg
Leading Article

Abstract

The phospholipids in the neuronal membranes of the brain are rich in highly unsaturated essential fatty acids (EFAs). It has been hypothesised that abnormalities of phospholipid metabolism are present in patients with schizophrenia and that the EFAs omega-3 polyunsaturated fatty acids, and eicosapentaenoic acid (EPA) in particular, may have a role in treating this illness. Considerable preclinical and clinical evidence provides support for this proposal. An epidemiological study reported a better outcome for patients with schizophrenia in countries where the diet is rich in unsaturated fatty acids. Evidence of abnormalities of EFAs has been found in erythrocyte membranes and cultured skin fibroblasts of patients with schizophrenia, and abnormal retinal function and niacin skin flush tests (markers of omega-3 polyunsaturated fatty acid depletion) have also been reported. Case reports and an open-label clinical trial reported efficacy for EPA in schizophrenia. Four randomised, controlled trials of EPA versus placebo as supplemental medication have now been reported. Two of these trials showed significant benefit with EPA on the positive and negative symptom scale total scores, whereas the other two did not show any effects on this primary efficacy measure. One study also reported a beneficial effect on dyskinesia. In the only published trial in which EPA was used as monotherapy versus placebo in schizophrenia, some evidence was found to suggest antipsychotic activity. Taken together, there is considerable evidence to suggest abnormalities of EFAs in cell membranes of patients with schizophrenia, and there is preliminary evidence that EPA is an effective adjunct to antipsychotics.

References

  1. 1.
    Emsley R. Partial response to antipsychotic treatment: the patient with enduring symptoms. J Clin Psychiatry 1999; 60 Suppl. 23: 10–3PubMedGoogle Scholar
  2. 2.
    Thomas CS, Lewis S. Which atypical antipsychotic? Br J Psychiatry 1998; 172: 106–9PubMedCrossRefGoogle Scholar
  3. 3.
    Marder SR. Management of treatment-resistant patients with schizophrenia. J Clin Psychiatry 1996; 57 Suppl. 11: 26–30PubMedGoogle Scholar
  4. 4.
    Carman J, Peuskens J, Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychopharmacol 1995; 10(4): 207–13PubMedCrossRefGoogle Scholar
  5. 5.
    Tollefson GD, Sanger TM, Lu Y, et al. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998; 55(3): 250–8PubMedCrossRefGoogle Scholar
  6. 6.
    Meltzer HY. Suicide and schizophrenia: clozapine and the Inter-SePT study: International Clozaril/Leponex Suicide Prevention Trial. J Clin Psychiatry 1999; 60 Suppl. 12: 47–50Google Scholar
  7. 7.
    Rossi A, Mancini F, Stratta P, et al. Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. Acta Psychiatr Scand 1997; 95(1): 40–3PubMedCrossRefGoogle Scholar
  8. 8.
    Franz M, Lis S, Pluddemann K, et al. Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. Br J Psychiatry 1997; 170: 422–5PubMedCrossRefGoogle Scholar
  9. 9.
    Beasley CM, Dellva MA, Tamura RN, et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999; 174: 23–30PubMedCrossRefGoogle Scholar
  10. 10.
    Weiden P, Aquila R, Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 1996; 57 Suppl. 11: 53–60PubMedGoogle Scholar
  11. 11.
    Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686–96PubMedGoogle Scholar
  12. 12.
    Clark C, Burge MR. Diabetes mellitus associated with atypical anti-psychotic medications. Diabetes Technol Ther 2003; 5(4): 669–83PubMedCrossRefGoogle Scholar
  13. 13.
    Melkersson KI, Dahl ML. Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology (Berl) 2003 Jul 8 [Epub ahead of print]Google Scholar
  14. 14.
    Emsley RA, Oosthuizen PP, Joubert AJ, et al. Treatment of schizophrenia in low-income countries. Int J Neuropsycho-pharmacol 1999; 2: 321–5CrossRefGoogle Scholar
  15. 15.
    Horrobin DF, Glen AI, Vaddadi K. The membrane hypothesis of schizophrenia. Schizophr Res 1994; 13(3): 195–207PubMedCrossRefGoogle Scholar
  16. 16.
    Horrobin DF, Manku MS. Clinical biochemistry of essential fatty acids. In: Horrobin DF, editor. Omega-6 essential fatty acids. New York: Wiley Liss, 1990: 21–53Google Scholar
  17. 17.
    Horrobin D, Bennett CN. Phospholipid spectrum disorders in psychiatry and neurology. 2nd ed. Carnforth, UK: Marius Press, 2003Google Scholar
  18. 18.
    Horrobin DF. Schizophrenia as a prostaglandin deficiency disease. Lancet 1977; I(8018): 936–7CrossRefGoogle Scholar
  19. 19.
    Horrobin DF. Schizophrenia as a membrane lipid disorder which is expressed throughout the body. Prostaglandins Leukot Essent Fatty Acids 1996; 55(1–2): 3–7PubMedCrossRefGoogle Scholar
  20. 20.
    Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophrenia Res 2001; 30: 193–208CrossRefGoogle Scholar
  21. 21.
    Nasrallah HA. Neurodevelopmental pathogenesis of schizophrenia. Psychiatr Clin North Am 1993; 16: 269–80PubMedGoogle Scholar
  22. 22.
    Sinclair HM. Deficiency of essential fatty acids and atherosclerosis et cetera. Lancet 1956; I: 381–3Google Scholar
  23. 23.
    McNeil TF, Cantor-Graae E, Nordstrom LG, et al. Head circumference in ‘preschizophrenic’ and control neonates. Br J Psychiatry 1993; 162: 517–23PubMedCrossRefGoogle Scholar
  24. 24.
    McNeil TF, Kaij L. Obstetric factors in the development of schizophrenia: complications in the births of preschizophrenics and in reproduction by schizophrenic patients. In: Wynne LC, Cromwell RL, Matthysee S, editors. The nature of schizophrenia. New York: John Wiley and Sons, 1978: 401–29Google Scholar
  25. 25.
    Selten JP, van Durursen R, van der Graaf C, et al. Second-trimester exposure to maternal stress is a possible factor for psychotic illness in the child [abstract]. Schizophr Res 1997; 24: 258CrossRefGoogle Scholar
  26. 26.
    Edwards RH, Peet M. Essential fatty acid intake in relation to depression. In: Peet M, Glen I, Horrobin DF, editors. Phospholipid spectrum disorder in psychiatry. Carnforth, UK: Marius Press, 1999Google Scholar
  27. 27.
    Kirsten GF, Smuts CM, Tichelaar HY, et al. The effect of severe pre-eclampsia on maternal and cord erythrocyte membrane essential fatty acid profiles. S Afr Med J 1998, 629Google Scholar
  28. 28.
    Mahadik SP, Evans D, Lal H. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25: 463–93PubMedCrossRefGoogle Scholar
  29. 29.
    Edwards R, Peet M, Shay J, et al. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J Affective Disord 1998; 48: 149–55CrossRefGoogle Scholar
  30. 30.
    Vaddadi KS. Essential fatty acids and movement disorders. In: Peet M, Glen I, Horrobin D, editors. Phospholipid spectrum disorder in psychiatry. Carnforth, UK: Marius Press, 1999Google Scholar
  31. 31.
    Puri B, Bydder GM, Counsell SJ, et al. MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment. Neuroreport 2002; 13: 123–6PubMedCrossRefGoogle Scholar
  32. 32.
    Christensen O, Christensen E. Fat consumption and schizophrenia. Acta Psychiatr Scand 1988; 78(5): 587–91PubMedCrossRefGoogle Scholar
  33. 33.
    Peet M, Laugharne J, Rangarajan N, et al. Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. J Psychiatr Res 1995; 29(3): 227–32PubMedCrossRefGoogle Scholar
  34. 34.
    Vaddadi KS, Gilleard CJ, Soosai E, et al. Schizophrenia, tardive dyskinesia and essential fatty acids. Schizophr Res 1996; 20(3): 287–94PubMedCrossRefGoogle Scholar
  35. 35.
    Mahadik SP, Mukherjee S, Horrobin DF, et al. Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal subjects. Psychiatry Res 1996; 63(2–3): 133–42PubMedCrossRefGoogle Scholar
  36. 36.
    Assies J, Lieverse R, Vreken P, et al. Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group. Biol Psychiatry 2001; 49: 510–22PubMedCrossRefGoogle Scholar
  37. 37.
    Yao J, Stanley JA, Reddy RD, et al. Correlations between peripheral polyunsaturated fatty acid content and in vivo membrane phospholipid metabolites. Biol Psychiatry 2002; 52: 823–30PubMedCrossRefGoogle Scholar
  38. 38.
    Glen AIM, Cooper SJ, Rybakowski J, et al. Membrane fatty acids, niacin flushing and clinical parameters. Prostaglandins Leukot Essent Fatty Acids 1996; 55: 9–15PubMedCrossRefGoogle Scholar
  39. 39.
    Ward PE, Sutherland J, Glen EM, et al. Niacin skin flush in schizophrenia: a preliminary report. Schizophr Res 1998; 29: 269–74PubMedCrossRefGoogle Scholar
  40. 40.
    Mahadik SP, Shendarkar NS, Scheffer RE, et al. Utilization of precursor essential fatty acids in culture by skin fibroblasts from schizophrenic patients and normal controls. Prostaglandins Leukot Essent Fatty Acids 1996; 55: 65–70PubMedCrossRefGoogle Scholar
  41. 41.
    Warner R, Laugharne J, Peet M, et al. Retinal function as a marker for cell membrane omega-3 fatty acid depletion in schizophrenia: a pilot study. Biol Psychiatry 1999; 45: 1138–42PubMedCrossRefGoogle Scholar
  42. 42.
    Skinner FK, MacDonell LEF, Glen I. Retinal function in schizophrenia. In: Peet M, Glen I, Horrobin DF, editors. Phospholipid spectrum disorder in psychiatry. Carnforth, UK: Marius Press, 1999: 121–31Google Scholar
  43. 43.
    Yao JK, Leonard S, Reddy RD. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr Res 2000; 42: 7–17PubMedCrossRefGoogle Scholar
  44. 44.
    Richardson AJ, Easton T, Gruzelier JH, et al. Laterality changes accompanying symptom remission in schizophrenia following treatment with eicosapentaenoic acid. Int J Psychophysiol 1999; 34(3): 333–9CrossRefGoogle Scholar
  45. 45.
    Su KP, Shen WW, Huang SY. Omega-3 fatty acids as a psychotherapeutic agent for a pregnant schizophrenic patient. Eur Neuropsychopharmacol 2001; 11(4): 295–9PubMedCrossRefGoogle Scholar
  46. 46.
    Laugharne JD, Mellor JE, Peet M. Fatty acids and schizophrenia. Lipids 1996; 31 Suppl.: S163–5PubMedCrossRefGoogle Scholar
  47. 47.
    Peet M, Brind J, Ramchand CN, et al. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res 2001; 49(3): 243–51PubMedCrossRefGoogle Scholar
  48. 48.
    Fenton WS, Dickerson F, Boronow J, et al. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 2001; 158(12): 2071–4PubMedCrossRefGoogle Scholar
  49. 49.
    Peet M, Horrobin DF. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res 2002; 36: 7–18PubMedCrossRefGoogle Scholar
  50. 50.
    Emsley R, Myburgh C, Oosthuizen P, et al. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 2002; 159(9): 1596–8PubMedCrossRefGoogle Scholar
  51. 51.
    Horrobin DF, Jenkins K, Bennett CN, et al. Eicosapentaenoic acid and arachidonic acid: collaboration and not antagonism is the key to biological understanding. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 83–90PubMedCrossRefGoogle Scholar
  52. 52.
    Laughren TP. The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: an FDA perspective. Eur Psychiatry 2001; 16: 418–23PubMedCrossRefGoogle Scholar
  53. 53.
    Fenton WS, Hibbeln J, Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol Psychiatry 2000; 47: 8–21PubMedCrossRefGoogle Scholar
  54. 54.
    Maidment ID. Are fish oils an effective therapy in mental illness: an analysis of the data. Acta Psychiatr Scand 2000; 102(1): 3–11PubMedCrossRefGoogle Scholar
  55. 55.
    Freeman MP. Omega-3 fatty acids in psychiatry: a review. Ann Clin Psychiatry 2000; 12: 159–65PubMedGoogle Scholar
  56. 56.
    Joy CB, Mumby-Croft R, Joy LA. Polyunsaturated fatty acid (fish or evening primrose oil) for schizophrenia. Cochrane Database Systematic Reviews. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 2. Oxford: Oxford Update Software, 2000: CD001257Google Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  • Robin Emsley
    • 1
  • Piet Oosthuizen
    • 1
  • Susan J. van Rensburg
    • 2
  1. 1.Department of Psychiatry, Faculty of Health SciencesUniversity of StellenboschCape TownSouth Africa
  2. 2.Department of Chemical Pathology, Faculty of Health SciencesUniversity of StellenboschCape TownSouth Africa

Personalised recommendations